Scythian Biosciences Applauds the UK Government’s Decision to Legalize Medical Cannabis

World News: . []

Scythian’s Chief Medical Officer, The Famed Dr. Barnes, Receives National Praise for His Advocacy, Education and Tireless Leadership from Government, Media and Medical Organizations to Assist in Making This Major Event Happen

TORONTO, Oct. 12, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "" or “”) (CSE:SCYB) (Frankfurt:9SB) (OTC – Nasdaq Intl:SCCYF) applauds the United Kingdom’s decision to allow specialist doctors the option to legally issue prescriptions for cannabis-based medicines when they believe patients could benefit from the treatment. Specialist doctors in England, Wales and Scotland will be able to prescribe cannabis-derived medicines in less than a month.

The law change, passed in Parliament yesterday, came after Home Secretary Sajid Javid listened to concerns from parents of children with conditions such as severe epilepsy. Over the summer an urgent review of cannabis-based medicinal products was called following an outcry over two young epilepsy sufferers, Alfie Dingley and Billy Caldwell, being denied access to cannabis oil.

“Congratulations to the UK Government and Home Secretary Sajid Javid, and a special congratulations to our own Chief Medical Officer, Michael Barnes, whose years of work, collaborative efforts with members of government and insatiable dedication to legalizing medicinal cannabis use helped make this decision occur,” said CEO Brady Cobb. “Scythian is proud to have you as a senior leader of our team and strongly supports your ongoing initiatives.”  

Professor Michael Barnes, a leading world authority in neurological rehabilitation and an influential leader in the medical cannabis sector, has been a powerful advocate for the medical use of cannabis in the United Kingdom. Through strategic relationships and key organizations such as, the United Patients Alliance and Clear, as well as his participation in the drug policy innovation hub Volteface, Professor Barns has helped facilitate the accomplishment of key milestones along the UK’s path to legalizing cannabis-derived medicines. One such milestone was reached this past July when Alfie Dingley became the first person in the UK to receive a long-term licence to be treated with medicinal cannabis.

Professor Barnes has lectured extensively on medical cannabis use across the globe, in addition to recording several live TV, radio, print and social media interviews on the topic. He has played an instrumental part in Sajid Javid’s groundbreaking decision to loosen regulations on prescribing medical cannabis in the UK.

“This is a historic day,” said Professor Michael Barnes. “Many people have campaigned for many years to get to this point. We still have a way to go, particularly for doctors’ education, but nevertheless beginning in November many tens of thousands of people with a whole range of medical conditions can at last access a medicine that will surely benefit their health.” 

Scythian is an international cannabis company with a focus on legal U.S. states. Its strategic investments and partnerships across cultivation, distribution and retail complement the company’s R&D program with the University of Miami. It is this comprehensive approach that is positioning Scythian as a future frontrunner in the United States medical cannabis industry.

Scythian Biosciences Corp.Brady Cobb, CEOPhone: (212) 729-9208Email:

For media inquiries, please contact:David Schull or Nic JohnsonRusso Partners(858) 717-2310

More news and information about Scythian Biosciences Corp.

Published By:

Globe Newswire: 13:15 GMT Friday 12th October 2018

Published: .

Search for other references to "scythian" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us